BMS 599626 inhibited vanadate-sensitive ABCG2 ATPase activity in insect-cell membrane vesicles in a concentration-dependent manner. In K-1 cells, treatment significantly lowered major signaling molecule levels in the EGFR/PI3K/AKT pathway compared with the negative control group. Treatment produced cell viability inhibition in A549 lung cancer cells. ABCG2 protein expression remained unchanged following treatment in resistant NCI-H460/MX20 cells. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Concentration-dependent inhibition of ABCG2 ATPase activity
Cell-based study · membrane vesicles of insect cells containing ABCG2 [1]
In membrane vesicles of insect cells containing ABCG2, BMS 599626 inhibited vanadate-sensitive ABCG2 ATPase activity in a concentration-dependent manner relative to basal activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–40 µM final concentration
- Method
- treated with BMS-599626
- Reported limits
- Not stated in the sentences used: schedule, vehicle.
Methods and source locations
Compound reported in the paper: BMS 599626
The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.
2. Results > 2.8. BMS-599626 Inhibits the ATPase of ABCG2 (S37); 4. Materials and Methods > 4.8. ATPase Assay (S82)
vanadate-sensitive ATPase activity of ABCG2: vanadate-sensitive ATPase activity of ABCG2; comparator: basal activity — 2. Results > 2.8. BMS-599626 Inhibits the ATPase of ABCG2 (S37); 4. Materials and Methods > 4.8. ATPase Assay (S82)
Signaling protein levels in K-1 cells
Cell-based study · K-1 [2]
In K-1 cells, treatment at 10 µM significantly lowered the levels of major signaling molecules in the EGFR/PI3K/AKT pathway compared with the negative control group, as assessed by Western blot analysis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- added after 24 h of cell culture; after 72 h of culture
- Method
- added
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: BMS 599626
The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.
Methods > Western blotting (S23, S24); Results > GALNT7 promotes cell proliferation and invasion by activating EGFR/PI3K/AKT pathway (S190, S191, S198)
Western blot analysis was used to detect the protein expression levels of EGFR, PI3K, p-PI3K, AKT, p-AKT and GALNT7: Western blot analysis was used to detect the protein expression levels of EGFR, PI3K, p-PI3K, AKT, p-AKT and GALNT7; comparator: negative control group — Results > GALNT7 promotes cell proliferation and invasion by activating EGFR/PI3K/AKT pathway (S191, S198)
Cell viability inhibition in lung cancer cells
Cell-based study · lung cancer cell line A549 [3]
In lung cancer A549 cells cultured in fresh medium, treatment inhibited cell viability after 48 h of incubation.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h of incubation
- Method
- cultured in fresh medium
- Vehicle
- DMSO (final concentration, 0.1%)
- Reported limits
- Not stated in the sentences used: dose, control.
Methods and source locations
Compound reported in the paper: BMS 599626
The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.
Methods > CCK8 assay to detect cell viability (S46, S47); Results > The suppression of the proliferation of human lung cancer cells by CEP-9722 and IMG (S150)
IC50 values: IC50 values — Results > The suppression of the proliferation of human lung cancer cells by CEP-9722 and IMG (S150)
ABCG2 protein expression in resistant cells
Cell-based study · NCI-H460/MX20 [1]
In resistant NCI-H460/MX20 cells, treatment at 300 nM for 72 h left ABCG2 protein expression unchanged.
Literature-Reported Treatment Conditions
- Treatment concentration
- 300 nM
- Exposure duration
- for 72 h
- Method
- treatment with 300 nM BMS-599626
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: BMS 599626
The paper names BMS 599626 without stating the salt or form; not verified as the hydrochloride form supplied as A11209. No dose conversion or lot validation.
2. Results > 2.7. BMS-599626 Does not Change the Total or Cell Membrane Expression of ABCG2 (S29); 4. Materials and Methods > 4.6. Immunoblotting (S76); Figure 6 legend (S113)
expression of ABCG2 protein: expression of ABCG2 protein; comparator: with or without BMS-599626 — 2. Results > 2.7. BMS-599626 Does not Change the Total or Cell Membrane Expression of ABCG2 (S29); Figure 6 legend (S113)